Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy

Prostate Cancer and Prostatic Diseases volume 12, pages 116–123 (2009)Cite this article

Abstract

The aim of this review is to provide a discussion of the diagnostic evaluation of biochemical recurrence following radical prostatectomy (RP) and an overview of the postoperative hormonal treatment (HT) options. As no randomized trials in the clinical setting of postoperative prostate-specific antigen recurrence have been reported, there is no conclusive evidence that HT after RP will prolong survival or reduce morbidity. Non-traditional approaches, such as intermittent androgen deprivation, non-steroidal anti-androgens and combination of finasteride and non-steroidal anti-androgen, are investigated and may be acceptable options. Combinations of HT with radiotherapy and/or chemotherapy for treatment of recurrent prostate cancer are under study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D . Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781–1788.

    Article  CAS  PubMed  Google Scholar 

  2. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al. Immediate versus deferred androgen deprivation treatment in patients with node positive prostate cancer after radical prostatectomy and pelvic lymhadenectomy. Lancet Oncol 2006; 7: 472–479.

    Article  CAS  PubMed  Google Scholar 

  3. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H . Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146–1151.

    Article  CAS  PubMed  Google Scholar 

  4. Freedland SJ, Sutter ME, Dorey F, Aronson WJ . Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61: 365–369.

    Article  PubMed  Google Scholar 

  5. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D′Amico AV, Dmochowski RR et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540–545.

    Article  CAS  PubMed  Google Scholar 

  6. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68–80.

    Article  PubMed  Google Scholar 

  7. Khan MA, Partin AW . Management of patients with an increasing prostate-specific antigen after radical prostatectomy. Curr Urol Rep 2004; 5: 179–187.

    Article  PubMed  Google Scholar 

  8. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC . Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–1597.

    Article  CAS  PubMed  Google Scholar 

  9. Bianco Jr FJ, Scardino PT, Eastham JA . Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (‘trifecta’). Urology 2005; 66 (5 Suppl): 83–94.

    Article  PubMed  Google Scholar 

  10. Yossepowitch O, Eggener SE, Bianco Jr FJ, Carver BS, Serio A, Scardino PT et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007; 178: 493–499; discussion 499.

    Article  PubMed  Google Scholar 

  11. Dotan ZA, Bianco Jr FJ, Rabbani F, Eastham JA, Fearn P, Scher HI et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005; 23: 1962–1968.

    Article  PubMed  Google Scholar 

  12. Deliveliotis C, Manousakas T, Chrisofos M, Skolarikos A, Delis A, Dimopoulos C . Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World J Urol 2007; 25: 309–313.

    Article  PubMed  Google Scholar 

  13. Tamsel S, Killi R, Apaydin E, Hekimgil M, Demirpolat G . The potential value of power Doppler ultrasound imaging compared with grey-scale ultrasound findings in the diagnosis of local recurrence after radical prostatectomy. Clin Radiol 2006; 61: 325–330; discussion 323–324.

    Article  CAS  PubMed  Google Scholar 

  14. Naya Y, Okihara K, Evans RB, Babaian RJ . Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology 2005; 66: 350–355.

    Article  PubMed  Google Scholar 

  15. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi S, Ciccariello M et al. Role of dynamic contrast-enhanced magnetic resonance (MR-) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008; 54: 589–600.

    Article  PubMed  Google Scholar 

  16. Barentsz J, Fütterer J, Takahashi S . Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients. Eur J Radiol 2007; 63: 369–372.

    Article  PubMed  Google Scholar 

  17. Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008; 190: 1187–1192.

    Article  PubMed  Google Scholar 

  18. Pucar D, Sella T, Schoder H . The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 2008; 18: 87–97.

    Article  PubMed  Google Scholar 

  19. Reske SN, Blumstein NM, Glatting G . [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008; 35: 9–17.

    Article  PubMed  Google Scholar 

  20. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007; 100: 786–793.

    Article  CAS  PubMed  Google Scholar 

  21. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C et al. The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 18–23.

    Article  CAS  PubMed  Google Scholar 

  22. Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P et al. Histological verification of (11)C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008.

  23. Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42: 25–30.

    Article  CAS  PubMed  Google Scholar 

  24. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52: 423–429.

    Article  PubMed  Google Scholar 

  25. Raj GV, Partin AW, Polascik TJ . Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002; 94: 987–996.

    Article  PubMed  Google Scholar 

  26. Sodee DB, Sodee AE, Bakale G . Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 2007; 37: 17–28.

    Article  PubMed  Google Scholar 

  27. Heidenreich A, Aus G, Abbou CC, Bolla M, Schmid HP, van Poppel H et al. European Association of Urology. EAU guidelines on prostate cancer. 2007; Available from www.uroweb.org/nc/professional-resources/guidelines/online.

  28. Alibhai SM, Gogov S, Allibhai Z . Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006; 60: 201–215.

    Article  PubMed  Google Scholar 

  29. Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ . The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176: 520–525.

    Article  PubMed  Google Scholar 

  30. Keating NL, O′Malley AJ, Smith MR . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448–4456.

    Article  CAS  PubMed  Google Scholar 

  31. Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U . Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 2006; 98: 20–27.

    Article  PubMed  Google Scholar 

  32. Gillatt D . Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J Cancer Res Clin Oncol 2006; 132 (Suppl 1): S17–S26.

    Article  CAS  PubMed  Google Scholar 

  33. Tunn U . The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 2007; 99 (Suppl 1): 19–22; discussion 23–14.

    Article  CAS  PubMed  Google Scholar 

  34. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initials results of the Medical Research Council Trial. Br J Urol 1997; 79: 235–246.

    Article  Google Scholar 

  35. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24: 1868–1876.

    Article  PubMed  Google Scholar 

  36. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004; 45: 267–270; discussion 270.

    Article  CAS  PubMed  Google Scholar 

  37. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247–254.

    Article  CAS  PubMed  Google Scholar 

  38. Zincke H, Lau W, Bergstralh E, Blute ML . Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001; 166: 2208–2215.

    Article  CAS  PubMed  Google Scholar 

  39. Seay TM, Blute ML, Zincke H . Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998; 159: 357–364.

    Article  CAS  PubMed  Google Scholar 

  40. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG . Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001; 91: 66–73.

    Article  CAS  PubMed  Google Scholar 

  41. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007; 178 (3 Part 1): 864–870; discussion 870–861.

    Article  PubMed  Google Scholar 

  42. Spiess PE, Lee AK, Busby JE, Jordan JJ, Hernandez M, Burt K et al. Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int 2007; 99: 321–325.

    Article  CAS  PubMed  Google Scholar 

  43. Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K . Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009; 27: 100–105.

    Article  PubMed  Google Scholar 

  44. Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston H et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol) 2007; 19: 167–171.

    Article  CAS  Google Scholar 

  45. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141–1147.

    Article  PubMed  Google Scholar 

  46. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML . Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol 2008; 179: 1830–1837; discussion 1837.

    Article  PubMed  Google Scholar 

  47. Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol 2008; 179: 156–161; discussion 161–152.

    Article  PubMed  Google Scholar 

  48. Moul JW . Treatment of PSA only recurrence of prostate cancer after prior local therapy. Curr Pharm Des 2006; 12: 785–798.

    Article  CAS  PubMed  Google Scholar 

  49. Conti PD, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ . Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007; 4: CD005009.

    Google Scholar 

  50. Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED . Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 2003; 62: 872–876.

    Article  PubMed  Google Scholar 

  51. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291: 1325–1332.

    Article  CAS  PubMed  Google Scholar 

  52. Stephenson AJ . Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006; 24, (No 18S (June 20 Supplement)) 4514.

    Google Scholar 

  53. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760–2769.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Pearce A, Choo R, Danjoux C, Morton G, Loblaw DA, Szumacher E et al. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 2006; 65: 78–83.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital, KU Leuven, Leuven, Belgium

    H Van Poppel, S Joniau & B Van Cleynenbreugel

  2. Department of Nuclear Medicine, University Hospital, KU Leuven, Leuven, Belgium

    F M Mottaghy

  3. Department of Radiology, University Hospital, KU Leuven, Leuven, Belgium

    R Oyen

Authors
  1. H Van Poppel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Joniau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Van Cleynenbreugel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F M Mottaghy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Oyen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Van Poppel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Poppel, H., Joniau, S., Van Cleynenbreugel, B. et al. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Prostate Cancer Prostatic Dis 12, 116–123 (2009). https://doi.org/10.1038/pcan.2009.3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2009.3

Keywords

Search

Advanced search

Quick links